Compare Abeona Therapeutics Inc (ABEO) vs Charter Communications Inc (CHTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Charter Communications Inc — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Charter Communications Inc trades at $133.14 (market cap $16.97B). The key difference: Charter Communications Inc is far larger — about 45.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Charter Communications Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | CHTR | |
|---|---|---|
Market Cap | $373.32M | $16.97B |
Sector | Health | Media |
52-Week High | $7.23 | $411.66 |
52-Week Low | $4.17 | $125.54 |
Enterprise Value | $228.22M | $113.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Charter Communications (CHTR) trades at $138.02, up 0.6% on the day, with a bearish technical signal but deeply discounted valuation metrics including a P/E of 3.66 and EV/EBITDA of 5.32. Recent news highlights a potential mobile partnership with SpaceX, driving significant pre-market gains, while financials show stable revenue near $54.8B and improving operating cash flow to $16.08B in 2025.
The stock presents a high-risk, high-reward opportunity, with a consensus price target of $214 suggesting 55% upside, but faces headwinds from high debt, competitive pressures, and inconsistent earnings beats. Investor sentiment is mixed, balancing low valuation against operational challenges and leverage concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
